Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the finding by the Competition and Markets Authority that drug companies had over-charged the National Health Service, what plans they have to reduce the price that the National Health Service pays for liothyronine.

Since 2016, several marketing authorisations have been granted for liothyronine, therefore the National Health Service reimbursement price in primary care has been reducing as a direct response to more competition in the market.